20% off: Here's why I think the Cochlear (ASX:COH) share price is a buy today

The Cochlear share price is 20% lower than its February high. Here's why I think it might be a good buying opportunity for investors today.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Cochlear Limited (ASX: COH) shares have not had a good year in 2020 so far. After topping out at a new (and still standing) all-time high of $251.55 back in February, the Cochlear share price is today asking just $200.50 at the time of writing. That's more than a 20% discount to the February high watermark. Now just because a share has pulled back 20% from its most recent high, this does not mean it's automatically 'on sale' or a 'good deal'. But it does merit some digging in my view, particularly when the company in question is as high calibre as Cochlear.

cheap cochlear share price represented by large green letters spelling out twenty percent

Image source: Getty images

Lend me your ears…

Cochlear is one of the most successful ASX shares in the healthcare space. It famously pioneered the 'Cochlear implant' – a hearing aid device now universally recognisable. The company has continued to remain in the vanguard of hearing aid technology and is still a market leader in the space. It now has a truly global presence, with 20% of its sales now coming from emerging markets. It holds a 60% share of its global product market.

However, like many ASX companies, both Cochlear and its shares have been under pressure this year due to the coronavirus pandemic. In its FY2020 earnings report released last month, Cochlear reported a loss of $238.3 million for the year on revenues of $1.35 billion, mostly due to surgery deferrals as a result of the pandemic. As such, the company will not be paying a final dividend in 2020.

Why is the Cochlear share price a buy today then?

I think Cochlear is worth a good look today, even after its disappointing earnings report. Yes, Cochlear has taken a massive hit this year. But the market that it serves (people with a hearing impairment) hasn't gone anywhere. Cochlear serves a large customer base with inelastic demand for its products. Many of the company's patients are born with a hearing impairment, which means they have a fair chance of being Cochlear customers for life. The company already has a dominant position in advanced economies around the world and as incomes rise in emerging markets, more and more potential customers are finding Cochlear as well.

As such, I think the pullback we've seen in the Cochlear share price this year presents a solid buying opportunity. Quality companies like Cochlear don't go on sale often, and so I think this is a rare chance to open a position or double-down if you already have one.

Sebastian Bowen has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of Cochlear Ltd. The Motley Fool Australia has recommended Cochlear Ltd. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Man with a sleep apnoea mask on whilst sleeping.
Healthcare Shares

Why ResMed shares are tumbling 6% today despite strong results

Here's what spooked investors.

Read more »

Scientist looking at a laptop thinking about the share price performance.
Healthcare Shares

Imricor Medical Systems shares: Philips declares compatibility for iMR products

Big news is catching the eye of investors on Friday.

Read more »

Broker looking at the share price on her laptop with green and red points in the background.
Earnings Results

ResMed posts strong Q4 earnings, lifts dividend

The sleep disorder treatment company had another record quarter.

Read more »

a doctor wearing a white coat with a stethoscope around her neck stares out a window with her hand to the side of her face as though in deep thought.
Healthcare Shares

Clarity Pharmaceuticals reports clinical trial milestones

Clarity Pharmaceuticals reported continued clinical progress for its prostate cancer imaging and therapy programs.

Read more »

Medical workers examine an x-ray or scan in a hospital laboratory.
Healthcare Shares

Are Neuren Pharmaceuticals shares a buy, hold or sell after rocketing 16%?

This healthcare stock keeps rising.

Read more »

Medical workers examine an x-ray or scan in a hospital laboratory.
Broker Notes

Up 64%, 3 reasons this expert predicts Pro Medicus shares will keep on giving

A leading expert forecasts more outperformance from the surging Pro Medicus share price.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Clarity Pharmaceuticals reports new SECuRE trial responses at higher dose

Clarity Pharmaceuticals reports further progress in its SECuRE prostate cancer trial, showing strong PSA responses and new complete responses at…

Read more »

Two lab workers fist pump each other.
Healthcare Shares

Neuren Pharmaceuticals share price rockets: record Q2 DAYBUE sales and royalty upgrade

Second quarter net sales of DAYBUE increased 30%.

Read more »